Under tight security, an Australian facility has manufactured 10,000 capsules of the psychedelic drug for the first time.

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to TSND-201 (methylone) for the treatment of posttraumatic stress disorder (PTSD).

The new drug application (NDA) for MDMA capsules (Lykos Therapeutics) is based on phase 3 studies showing significant improvements in PTSD symptoms without serious adverse events.

For Lykos Therapeutics and the company’s would-be MDMA-assisted therapy for post-traumatic stress disorder (PTSD), the hits just keep coming. Earlier this month, Lykos was struck by an FDA ...

The psychedelic drug MDMA is near the end of a decades-long effort to enter mainstream medicine but instead of celebrating, supporters now find themselves wondering if the treatment will actually ...

Advocates haven't given up on MDMA therapy getting FDA approval : Shots - Health News With support from both sides in Congress, advocates are still fighting to get the psychedelic drug approved as ...

Despite spearheading the clinical trials for MDMA, Dr. Doblin is not a scientist. He holds a Ph.D. in public policy from Harvard’s Kennedy School of Government, where he did his dissertation on ...

The VA is investing $1.5 million to conduct the study over five years using pharmaceutical-grade MDMA while closely monitoring test subjects to ensure their well-being while participating in the ...

MDMA research also is already underway at Yale University, where the Defense Department awarded a three-year, $1 million grant in 2023 to study the effects of MDMA and a synthetic form of the ...